About

Our Vision

Big pharmaceutical companies have failed to innovate and develop better ways to address gout for over 40 years. Recognizing that the human GI tract has a massively underused potential for uric acid elimination, we realized that we could take advantage of this using microbes engineered to take up and break down uric acid.

We are creating next-generation probiotics that are affordable, accessible, and broadly effective. We solve your gout using engineered probiotics and cutting-edge biotechnology.

Our Technology

Theraneutrics is developing Krystalase, a patent-pending probiotic supplement specifically engineered to take up and break down uric acid in the gut.

We are screening dozens of prototypes to optimize performance and identify the most effective active ingredient for Krystalase. We are currently in the R&D phase to rigorously prove Krystalase is safe for your liver, kidneys, and rest of your body, and is effective in breaking down uric acid.

People with gout will be able to benefit from our proprietary technology exclusively through Krystalase.

Our Story

Theraneutrics was founded in 2018 and is currently working hard to solve your gout through diligent scientific research and development. We expect Krystalase to be available in U.S. markets mid-late 2022. Join our mailing list to keep up with our progress and be first in line to purchase Krystalase.

Join Our Team

Partner with Theraneutrics and see science-backed biotechnology change lives

Our team

Christoph Geisler

CEO & Founder

Dr. Geisler is the visionary and inventor of Theraneutrics’ biotechnology. Christoph holds a PhD. in Molecular Biology from the University of Wyoming and a bachelor’s degree in chemical engineering from Zuyd University of Applied Science.

James Francis

Chief Development Officer

James oversees the business development of Theraneutrics. A serial entrepreneur, he values the impact of Theraneutrics on customers. He received an MBA and master’s in engineering from the University of Wyoming.

Kaylee Bass

Business Intern

Kaylee is a senior in the College of Business at the University of Wyoming majoring in Business Management and Accounting. She works on customer outreach and social media presence.

July 6, 2020

National Science Foundation Small Business Innovation Research Phase 1 Grant

This week, the National Science Foundation (NSF) awarded Theraneutrics a small business innovation research (SBIR) Phase I grant worth $225,000. During the 12 month Phase I research, Christoph Geisler, founder and CEO of Theraneutrics, will lead a study to optimize engineered probiotics and test if they can safely and effectively treat elevated uric acid levels in an animal model.

Uric acid is a compound that is a normal product of healthy human metabolism. If uric acid levels rise too high, needle-sharp uric acid crystals form in joints. The result is gout, characterized by extremely painful inflammation and joint erosion.

Prescription gout drugs all have serious side effects and are not effective for many gout patients in lowering uric acid to a safe level. Supplements that are marketed towards gout fail to address the root cause of gout and do not lower uric acid levels at all.

Theraneutrics is developing a probiotic supplement specifically engineered to biodegrade uric acid and lower uric acid levels, thereby addressing the root cause of gout. Unlike prescription gout drugs, probiotics don’t enter the circulation, making them inherently safer. Moreover, Theraneutrics’ product is designed to be affordable and accessible, so you don't need to have expensive health insurance.

Theraneutrics